BioCryst Pharmaceuticals Ownership | Who Owns BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals Ownership Summary
BioCryst Pharmaceuticals is owned by 51.43% institutional investors, 1.15% insiders, and 47.42% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.74% of BCRX shares. BioPharma Credit Ord is the top mutual fund, with 8.23% of its assets in BioCryst Pharmaceuticals shares.
BCRX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | BioCryst Pharmaceuticals | 51.43% | 1.15% | 47.42% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 22.65M | 10.74% | $215.64M |
| Vanguard group | 22.27M | 10.60% | $173.73M |
| Blackrock | 19.96M | 9.68% | $123.33M |
| Ra capital management | 15.83M | 7.50% | $150.67M |
| Deerfield management company, l.p. (series c) | 15.04M | 7.13% | $143.16M |
| State street | 12.21M | 5.79% | $116.22M |
| Tcg crossover management | 11.02M | 5.22% | $104.92M |
| Janus henderson group | 8.91M | 4.22% | $84.85M |
| Perceptive advisors | 7.43M | 3.52% | $70.77M |
| Vestal point capital, lp | 7.03M | 3.33% | $66.88M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Rp management | 3.85M | 12.84% | $29.23M |
| Rosalind advisors | 923.06K | 3.53% | $8.79M |
| Kynam capital management, lp | 5.68M | 3.34% | $54.08M |
| Tcg crossover management | 11.02M | 3.00% | $104.92M |
| Vestal point capital, lp | 7.03M | 1.87% | $66.88M |
| Deerfield management company, l.p. (series c) | 15.04M | 1.69% | $143.16M |
| Parkman healthcare partners | 1.71M | 1.68% | $16.26M |
| Ra capital management | 15.83M | 1.60% | $150.67M |
| Eversept partners, lp | 3.04M | 1.53% | $28.94M |
| Perceptive advisors | 7.43M | 1.38% | $70.77M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tcg crossover management | 11.02M | 3.00% | 11.02M |
| Vestal point capital, lp | 7.03M | 1.87% | 4.78M |
| Perceptive advisors | 7.43M | 1.38% | 4.27M |
| Abrdn | 5.04M | 0.08% | 4.13M |
| Frazier life sciences management | 4.01M | 0.98% | 4.01M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Kynam capital management, lp | 5.68M | 3.34% | -3.69M |
| Braidwell lp | - | - | -3.38M |
| Avoro capital advisors | 1.25M | 0.12% | -3.25M |
| Baker bros. advisors lp | - | - | -2.82M |
| Qube research | - | - | -2.16M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tcg crossover management | 11.02M | 3.00% | 11.02M | $104.92M |
| Frazier life sciences management | 4.01M | 0.98% | 4.01M | $38.17M |
| Rfg advisory | 2.87M | 0.50% | 2.87M | $27.33M |
| Candriam s.c.a. | 2.29M | 0.11% | 2.29M | $21.77M |
| Vanguard fiduciary trust | 1.66M | 0.00% | 1.66M | $15.84M |
Sold Out
| Holder | Change |
|---|---|
| Tfo-tdc | -3.00 |
| Financial gravity asset management | -8.00 |
| Newedge advisors | -11.00 |
| Dinuzzo private wealth | -13.00 |
| Newbridge financial services group | -15.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 211 | -27.49% | 108,497,915 | -48.95% | 51 | 0.50% | 123 | -13.99% | 48 | -52.00% |
| Dec 31, 2025 | 79 | -73.04% | 34,367,278 | -82.30% | 16 | 0.19% | 37 | -72.79% | 25 | -75.49% |
| Sep 30, 2025 | 101 | -65.88% | 38,849,402 | -78.37% | 18 | 0.25% | 42 | -73.58% | 35 | -57.83% |
| Jun 30, 2025 | 304 | 9.35% | 196,946,754 | 15.72% | 94 | 1.42% | 161 | 5.92% | 86 | 30.30% |
| Mar 31, 2025 | 277 | 2.59% | 174,118,175 | 3.86% | 83 | 1.27% | 150 | 29.31% | 66 | -25.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BioPharma Credit Ord | 17.22M | 8.23% | 17.22M |
| Vanguard Total Stock Mkt Idx Inv | 8.04M | 3.16% | 24.91K |
| Vanguard US Total Market Shares ETF | 6.57M | 3.14% | -18.55K |
| State Street® SPDR® S&P® Biotech ETF | 7.42M | 2.92% | -73.40K |
| iShares Russell 2000 ETF | 5.33M | 2.10% | 44.98K |
| SPDR® S&P Biotech ETF | 3.67M | 1.75% | 8.19K |
| Vanguard Small Cap Index | 2.88M | 1.13% | -11.49K |
| ACAP Strategic A | 2.70M | 1.08% | -121.24K |
| Vanguard Institutional Extnd Mkt Idx Tr | 2.72M | 1.07% | 30.09K |
| Fidelity Small Cap Index | 2.28M | 0.90% | 26.36K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 18, 2026 | McKee Amy E | - | Sell | $100.28K |
| May 13, 2026 | Barnes Alane P | Chief Legal Officer | Sell | $596.25K |
| Mar 20, 2026 | HEGGIE THERESA | - | Sell | $504.82K |
| Mar 16, 2026 | Barnes Alane P | Chief Legal Officer | Sell | $1.37M |
| Dec 22, 2025 | Barnes Alane P | Chief Legal Officer | Sell | $166.56K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | - | - |
| 2026 Q1 | - | - |
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | - |
BCRX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools